Resistance to Pyrazinamide and Ethambutol Compromises MDR/XDR-TB Treatment (Clinical Practice) (Clinical Report)

Resistance to Pyrazinamide and Ethambutol Compromises MDR/XDR-TB Treatment (Clinical Practice) (Clinical Report)

The increase in multidrug-resistant tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis resistant in vitro to at least isoniazid (INH) and rifampicin (RIF), is a global concern. It is estimated that 511 000 MDR-TB cases occur globally each year. The World Health Organization (WHO) consequently released an emergency update on their management guidelines, recommending that treatment of MDR-TB should include at least 4 effective drugs, and that standardised treatment regimens should be based on resistance patterns for each country/region. Most importantly, treatment regimens should not depend on the results of drug susceptibility testing (DST) for ethambutol (EMB) or pyrazinamide (PZA). In response, the South African Department of Health prepared a draft drug-resistant TB treatment policy in which PZA remains one of the 4 effective drugs, while EMB should be replaced with terizidone or cycloserine, if there is resistance to EMB (disregarding inaccurate DST). In South Africa, there is a high frequency of undetected EMB and PZA resistance and their association with MDR-TB. Therefore, we recommend that the WHO guidelines in which 4 other effective drugs are used to treat MDR-TB, be followed more closely. EMB and PZA can be included if they are not counted as one of the 4 effective drugs. However, this does not address the root cause of the amplification of resistance in undiagnosed MDR-TB patients in South Africa, which can only be achieved by the implementation of rapid DST methods in all TB cases before initiating therapy. This protocol would curb the amplification of resistance and the evolution of XDR-TB. The number of MDR-TB cases has steadily increased despite the widespread implementation of the directly observed treatment short-course (DOTS) and DOTS-plus strategies. (1,2) A survey in South Africa estimates that 1.8% of new TB cases and 6.7% of retreatment TB cases are MDR-TB, (1) equating to approximately 14 000 MDR-TB cases each year. (1) The manner in which the WHO DOTS strategy has been implemented in South Africa to control TB might have inadvertently lead to the amplification of resistance in MDR-TB cases. (3-5) Consequently, it is important to review the epidemiology of drug resistance in the country and make informed evidence-based suggestions on improving the current treatment strategy.

Resistance to Pyrazinamide and Ethambutol Compromises MDR/XDR-TB Treatment (Clinical Practice) (Clinical Report)



Here is Download Link

Guidelines For The Programmatic Management Of Drug Resistant Tuberculosis


Guidelines For The Programmatic Management Of Drug Resistant Tuberculosis Read Online Download

Author by : Stop TB Initiative (World Health Organization)
Languange Used : en
Release Date : 2008
Publisher by : World Health Organization






Global Tuberculosis Report 2015


Global Tuberculosis Report 2015 Read Online Download

Author by : World Health Organization
Languange Used : en
Release Date : 2015
Publisher by : World Health Organization






Global Tuberculosis Report 2013


Global Tuberculosis Report 2013 Read Online Download

Author by : World Health Organization
Languange Used : en
Release Date : 2013
Publisher by : World Health Organization






Disease Control Priorities Third Edition Volume 6


Disease Control Priorities Third Edition Volume 6 Read Online Download

Author by : King K. Holmes
Languange Used : en
Release Date : 2017-11-06
Publisher by : World Bank Publications






Management Of Mdr Tb


Management Of Mdr Tb Read Online Download

Author by : World Health Organization
Languange Used : en
Release Date : 2009
Publisher by : World Health Organization






The New Profile Of Drug Resistant Tuberculosis In Russia


The New Profile Of Drug Resistant Tuberculosis In Russia Read Online Download

Author by : Russian Academy of Medical Sciences
Languange Used : en
Release Date : 2011-07-07
Publisher by : National Academies Press






Hiv Tb Drug Resistance Clinical Management Case Book


Hiv Tb Drug Resistance Clinical Management Case Book Read Online Download

Author by :
Languange Used : en
Release Date : 2013
Publisher by : BioAfrica and SATuRN






Leave a Reply

Your email address will not be published. Required fields are marked *